Related Experiment Video
Updated: May 20, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Research Progress in Chemokine Ligand 13 as a Potential Therapeutic Target in the Tumor Microenvironment of
Cai-Ling Shao1,2, Yan-Li Yang1, Peng-Fei Zhang1,2
1Department of Pathology, The 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, China.
Abstract:
Colorectal cancer is one of the most common malignant tumors in the digestive system and the third leading cause of malignant tumor-related deaths globally.The lack of effective therapeutic drug targets and biomarkers has resulted in low survival rates of colorectal cancer patients.In recent years,increasing studies have shown that the expression of chemokine ligand 13 (CXCL13) in the tumor microenvironment is closely related to tumor progression,prognosis,and response to immunotherapy.Especially in colorectal cancer,CXCL13 exhibits great potential as a potential marker for immune checkpoint therapy and its related T-cell subpopulations as immunotherapeutic targets.In this article,we review the research progress in CXCL13 in terms of its biological properties,association with the tumor microenvironment,related T-cell subpopulations,and targeted therapeutic strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
